The ORIGIN (Outcome Reduction With Initial Glargine Intervention) trial10 randomized 12 537 individuals with cardiovascular risk factors plus impaired fasting glucose levels, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine or standard care. This evidence concerns the gene INS and type 2 diabetes mellitus.